Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma, for Which No Standard Therapy Is Available

NCT00978523 is registered in ClinicalTrials.gov with Arno Therapeutics as lead sponsor.

NCT NCT00978523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00978523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma, for Which No Standard Therapy Is Available
Lead sponsor
Arno Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2009
Completion date
November 30, 2013
Enrollment
35 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumors